EICHOR
● Completed
A Study of the Change in Early and Sustained Pain Control in Axial Spondylarthritis in Adult Participants Receiving Upadacitinib
Condition: Axial Spondylarthritis (axSpA) · Sponsor: AbbVie
About this study
Axial spondyloarthritis (axSpA) is an immune-mediated inflammatory disease primarily affecting the axial skeleton. The most frequent axSpA symptom is chronic, often inflammatory back pain (IBP) that might be difficult to distinguish from other causes of chronic back pain (CBP). Many participants report persistent pain, including back pain, which impacts disease activity and quality of life including creating burdens such as sleep disturbance, social isolation, loss of productivity, as well as anxiety and depression. This study will assess the real-world effectiveness of upadacitinib on early and sustained pain control, and the association between pain and clinical/patient-reported outcomes in axSpA participants. Upadacitinib is being developed for the treatment of axSpA. Approximately 650 adult participants with active-axSpA will be enrolled across approximately 19 countries in Europe, North America, South America, and Asia-Pacific. Participants will receive oral upadacitinib tablets as prescribed by the physician prior to enrolling in this study in accordance with the terms of the local marketing authorization and professional and reimbursement guidelines with regards to dose, population and indication. Participants will be followed for 12 months. There may be a higher burden for participants in this study compared to usual standard of care. Participants will attend regular visits per routine clinical practice. The effect of the treatment will be checked by medical assess…
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (160)
| Hospital Italiano La Plata /ID# 230779 | La Plata, Buenos Aires, Argentina | — |
| CER Instituto Medico /ID# 230782 | Quilmes, Buenos Aires, Argentina | — |
| Instituto CAICI S.R.L /ID# 230781 | Rosario, Santa Fe Province, Argentina | — |
| Duplicate_CIMER /ID# 230780 | San Miguel de Tucumán, Tucumán Province, Argentina | — |
| Clinica Regional del Sud /ID# 248866 | Río Cuarto, Argentina | — |
| Paratus Clinical Research Woden /ID# 231460 | Phillip, Australian Capital Territory, Australia | — |
| Genesis Research Services /ID# 231593 | Broadmeadow, New South Wales, Australia | — |
| Campbelltown Hospital /ID# 231462 | Campbelltown, New South Wales, Australia | — |
| Royal Prince Alfred Hospital /ID# 232417 | Camperdown, New South Wales, Australia | — |
| BJC Health /ID# 230066 | Parramatta, New South Wales, Australia | — |
| Barwon Rheumatology Services /ID# 230068 | Geelong, Victoria, Australia | — |
| Peninsula Rheumatology /ID# 240172 | Langwarrin, Victoria, Australia | — |
+ 148 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04846244